Cover Image
市場調查報告書

革蘭氏陰性菌感染症:全球臨床實驗檢討

Gram-Negative Bacterial Infections Global Clinical Trials Review, H2, 2014

出版商 GlobalData 商品編碼 320831
出版日期 內容資訊 英文 123 Pages
訂單完成後即時交付
價格
Back to Top
革蘭氏陰性菌感染症:全球臨床實驗檢討 Gram-Negative Bacterial Infections Global Clinical Trials Review, H2, 2014
出版日期: 2014年11月30日 內容資訊: 英文 123 Pages
簡介

本報告提供革蘭氏陰性菌感染症的臨床試驗相關之基本資料及數據,為您彙整實驗數量及受驗者的募集情況,各階段趨勢,臨床試驗的主要製藥企業及研究機關簡介等資料。

簡介

  • 革蘭氏陰性菌感染症
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區的主要5個國家的臨床實驗數量
    • 歐洲的主要5個國家的臨床實驗數量
    • 北美的主要國家的臨床實驗數量
    • 中東·非洲的主要5個國家臨床實驗數量
    • 中南美的主要5個國家臨床實驗數量

G7各國臨床實驗數量:感染症臨床實驗上革蘭氏陰性菌感染症所佔的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:感染症臨床實驗上革蘭氏陰性菌感染症所佔的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗上目標達成情形

未完成的臨床實驗數量

一定期間所採用的實驗對象

贊助商類別的臨床實驗數量

有潛力的贊助商

革蘭氏陰性菌感染症治療藥臨床實驗的主要參與企業

有潛力的藥劑

最新臨床實驗新聞 革蘭氏陰性菌感染症

臨床實驗簡介

  • 主要企業臨床實驗概要
    • GlaxoSmithKline plc
    • Sanofi
    • Novartis AG
    • Merck & Co., Inc.
    • Gilead Sciences, Inc.
    • AstraZeneca PLC
    • Prokarium Ltd.
    • Pfizer Inc.
    • Actavis plc
  • 有代表性的研究機關·醫院臨床實驗概要
    • The National Institute of Allergy and Infectious Diseases
    • National Taiwan University Hospital
    • University of Pittsburgh
    • International Vaccine Institute
    • Radboud University
    • University of Oxford
    • Centers for Disease Control and Prevention
    • Tehran University of Medical Sciences
    • Eunice Kennedy Shriver National Institute of Child Health and Human Development
    • University of California, San Francisco

5個有代表性的臨床實驗簡介

附錄

目錄
Product Code: GDHC2444CTIDB

GlobalData's clinical trial report, "Gram-Negative Bacterial Infections Global Clinical Trials Review, H2, 2014" provides data on the Gram-Negative Bacterial Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gram-Negative Bacterial Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gram-Negative Bacterial Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Gram-Negative Bacterial Infections
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Gram-Negative Bacterial Infections
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Gram-Negative Bacterial Infections Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Gram-Negative Bacterial Infections
    • Nov 05, 2014: The Medicines Company Announces First Patient Enrollment in Phase 3 Studies of CARBAVANCE in Development for the Treatment of Serious Bacterial Infections Due to Gram-Negative Bacteria
    • Oct 09, 2014: Novel Siderophore Cephalosporin S-649266 Pre-Clinical Results Suggest Potent Activity Against Multidrug-Resistant Gram-Negative Pathogens
    • Sep 08, 2014: Shionogi Presents Pre-Clinical and Phase I Results For S-649266, A Novel Siderophore Cephalosporine Antibiotic With Potential To Treat Multidrug-Resistant Gram-Negative Pathogens
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • GlaxoSmithKline plc
      • Clinical Trial Overview of GlaxoSmithKline plc
      • Sanofi
      • Clinical Trial Overview of Sanofi
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • Merck & Co., Inc.
      • Clinical Trial Overview of Merck & Co., Inc.
      • Gilead Sciences, Inc.
      • Clinical Trial Overview of Gilead Sciences, Inc.
      • AstraZeneca PLC
      • Clinical Trial Overview of AstraZeneca PLC
      • Prokarium Ltd.
      • Clinical Trial Overview of Prokarium Ltd.
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • Actavis plc
      • Clinical Trial Overview of Actavis plc
    • Clinical Trial Overview of Top Institutes / Government
      • The National Institute of Allergy and Infectious Diseases
      • Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases
      • National Taiwan University Hospital
      • Clinical Trial Overview of National Taiwan University Hospital
      • University of Pittsburgh
      • Clinical Trial Overview of University of Pittsburgh
      • International Vaccine Institute
      • Clinical Trial Overview of International Vaccine Institute
      • Radboud University
      • Clinical Trial Overview of Radboud University
      • University of Oxford
      • Clinical Trial Overview of University of Oxford
      • Centers for Disease Control and Prevention
      • Clinical Trial Overview of Centers for Disease Control and Prevention
      • Tehran University of Medical Sciences
      • Clinical Trial Overview of Tehran University of Medical Sciences
      • Eunice Kennedy Shriver National Institute of Child Health and Human Development
      • Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development
      • University of California, San Francisco
      • Clinical Trial Overview of University of California, San Francisco
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Region, 2014*
  • Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014*
  • Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014*
  • Gram-Negative Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Gram-Negative Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014*
  • Gram-Negative Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Gram-Negative Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Gram-Negative Bacterial Infections Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Gram-Negative Bacterial Infections Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Gram-Negative Bacterial Infections Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Gram-Negative Bacterial Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Prokarium Ltd., 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Actavis plc, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by International Vaccine Institute, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Radboud University, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Oxford, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Centers for Disease Control and Prevention, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014*

List of Figures

  • Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014*
  • Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014*
  • Gram-Negative Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Gram-Negative Bacterial Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Gram-Negative Bacterial Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014*
  • Gram-Negative Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Gram-Negative Bacterial Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Gram-Negative Bacterial Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Gram-Negative Bacterial Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Gram-Negative Bacterial Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top